The NMDA NR2B Subunit-Selective Receptor Antagonist, CP-101,606, Enhances the Functional Recovery and Reduces Brain Damage after Cortical Compression-Induced Brain Ischemia

Journal of Neurotrauma

Volumn 21, Issue 1, 2004, Pages 83-93

  Kundrotiene, Jurgita ^a   Cebers, Gvido ^a   Wägner, Anna ^a   Liljequist, Sture ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Beam walking; Cerebral ischemia; CP 101,606; Fluoro Jade; Neuroprotection; NMDA NR2B receptor subunits

Indexed keywords

DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; FLUORESCENT DYE; FLUOROJADE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RECEPTOR SUBUNIT; TRAXOPRODIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; HIPPOCAMPUS; HISTOCHEMISTRY; IN VIVO STUDY; MALE; NERVE CELL NECROSIS; NERVE COMPRESSION; NEUROPROTECTION; NONHUMAN; PARESIS; RAT; SENSORIMOTOR CORTEX; THALAMUS; WALKING;

EID: 0942290536     PISSN: 08977151     EISSN: None     Source Type: Journal    
DOI: 10.1089/089771504772695977     Document Type: Article

References (64)

1. BACHURIN, S., TKACHENKO, S., BASKIN, I., et al. (2001). Neuroprotective and cognition-enhancing properties of MK-801 flexible analogs. Structure-activity relationships. Ann. N.Y. Acad. Sci. 939, 219-236.
2. BOND, A., LODGE, D., HICKS, C.A., et al. (1999). NMDA receptor antagonism, but not AMPA receptor antagonism attenuates induced ischaemic tolerance in the gerbil hippocampus. Eur. J. Pharmacol. 380, 91-99.
3. BOYCE, S., WYATT, A., WEBB, J.K., et al. (1999). Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 38, 611-623.
4. BRIMECOMBE, J.C., GALLAGHER, M.J., LYNCH, D.R., et al. (1998). An NR2B point mutation affecting haloperidol and CP101,606 sensitivity of single recombinant N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 286, 627-634.
5. BULLOCK, M.R., LYETH, B.G., and MUIZELAAR, J.P. (1999). Current status of neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies. Neurosurgery. 45, 207-220.
6. BULLOCK, M.R., MERCHANT, R.E., CARMACK, C.A., et al. (1999). An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage. Ann. N.Y. Acad. Sci. 890, 51-58.
7. BUTLER, T.W., BLAKE, J.F., BORDNER, J., et al. (1998). (3R,4S)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol: a conformationally restricted analogue of the NR2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol. J. Med. Chem. 41, 1172-1184.
8. CHAZOT, P.L., LAWRENCE, S., and THOMPSON, C.L. (2002). Studies on the subtype selectivity of CP-101,606: evidence for two classes of NR2B-selective NMDA receptor antagonists. Neuropharmacology 42, 319-324.
9. CHEN, Z. (2001). Experimental and clinical perspective in stroke: evaluation by behavior, magnetic resonance imaging and morphology [Thesis]. Karolinska Institutet, Stockholm.
10. CHENARD, B.L., BORDNER, J., BUTLER, T.W., et al. (1995). (1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenyl-piperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J. Med. Chem. 38, 3138-3145.
11. CHENARD, B.L., and MENNITI, F.S. (1999). Antagonists selective for NMDA receptors containing the NR2B subunit. Curr. Pharm. Des. 5, 381-404.
12. DANYSZ, W., and PARSONS, C.G. (1998). Glycine B recognition site of NMDA receptors and its antagonists. Amino Acids 14, 205-206.
13. DI, X., BULLOCK, R., WATSON, J., et al. (1997). Effect of CP101,606, a novel NR2B subunit antagonist of the N-methyl-D-aspartate receptor, on the volume of ischemic brain damage of cytotoxic brain edema after middle cerebral artery occlusion in the feline brain. Stroke 28, 2244-2251.
14. DOBLE, A. (1999). The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. 81, 163-221.
15. DUNAH, A.W., YASUDA, R.P., LUO, J., et al. (1999). Biochemical studies of the structure and function of the N-methyl-D-aspartate subtype of glutamate receptors. Mol. Neurobiol. 19, 151-179.
16. FEENEY, D.M., GONZALES, A., and LAW, W.A. (1982). Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 217, 855-857.
17. FIX, A.S., HORN, J.W., WIGHTMAN, K.A., et al. (1993). Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp. Neurol. 123, 204-215.
18. FREEDMAN, N.L. (1992). A sliding gas-delivery system and ventilating chamber for small animals fixed in standard stereotaxis instruments. Beh. Res. Methods Instr. Comp. 24, 423-425.
19. FREYALDENHOVEN, T.E., ALI, S.F., and SCHMUED, L.C. (1997). Systemic administration of MPTP induces thalamic neuronal degeneration in mice. Brain Res. 759, 9-17.
20. GILL, R., and LODGE, D. (1994). The neuroprotective effects of the decahydroisoquinoline, LY 215490; a novel AMPA antagonist in focal ischaemia. Neuropharmacology 33, 1529-1536.
21. GOTTI, B., DUVERGER, D., BERTIN, J., et al. (1988). Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia. J. Pharmacol. Exp. Ther. 247, 1211-1221.
22. GRABB, M.C., and CHOI, D.W. (1999). Ischemic tolerance in murine cortical cell culture: critical role for NMDA receptors. J. Neurosci. 19, 1657-1662.
23. GREENE, J.G., and GREENAMYRE, J.T. (1996). Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol. 48, 613-634.
24. HASHIMOTO, K., FUJIMURA, M., and YAMAGAMI, K. (2000). Dizocilpine-induced neuropathological changes in rat retrosplenial cortex are reversed by subsequent clozapine treatment. Life Sci. 11, 1071-1078.
25. HICKS, C.A., WARD, M.A., RAGUMOORTHY, N., et al. (1999). Evaluation of glycine site antagonists of the NMDA receptor in global cerebral ischemia. Brain Res. 819, 65-74.
26. HOLLMANN, M., and HEINEMANN, S. (1994). Cloned glutamate receptors. Annu. Rev. Neurosci. 17, 31-108.
27. HOPKINS, K.J., WANG, G., and SCHMUED, L.C. (2000). Temporal progression of kainic acid induced neuronal and myelin degeneration in the rat forebrain. Brain Res. 864, 69-80.
28. KEW, J.N., TRUBE, G., and KEMP, J.A. (1998). State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist. Br. J. Pharmacol. 123, 463-472.
29. KOVÁCS, A.D., CEBERS, G., CEBERE, A., et al. (2001). Cortical and striatal neuronal cultures of the same embryonic origin show intrinsic differences in glutamate receptor expression and vulnerability to excitotoxicity. Exp. Neurol. 168, 47-62.
30. KOVÁCS, A.D., CEBERS, G., CEBERE, A., et al. (2002). Selective and AMPA receptor-dependent astrocyte death following prolonged blockade of glutamate reuptake in rat cerebral cultures. Exp. Neurol. 174, 58-71.
31. KUNDROTIENİ, J., WÄGNER, A., and LILJEQUIST, S. (2000). The NMDA NR2B subunit selective antagonist, CP-101,606, improves the functional recovery after brain ischemia produced by mild compression of sensorimotor cortex. Presented at the Annual Meeting of the Society for Neuroscience, New Orleans.
32. KUNDROTIENİ, J., WÄGNER, A., and LILJEQUIST, S. (2002). Extradural compression of sensorimotor cortex: a useful model for studies on ischemic brain damage and neuroprotection. J. Neurotrauma 19, 69-84.
33. LEES, K.R., ASPLUND, K., CAROLEI, A., et al. (2000). Glycine antagonist (Gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 355, 1949-1954.
34. LEES, K.R., LAVELLE, J.F., CUNHA, L., et al. (2001). Glycine antagonist (GV150526) in acute stroke: a multicentre, double-blind placebo-controlled phase II trial. Cerebrovasc. Dis. 11, 20-29.
35. LIPTON, P. (1999). Ischemic cell death in brain neurons. Physiol. Rev. 79, 1431-1568.
36. LYDEN, P.D., and LONZO, L. (1994). Combination therapy protects ischemic brain in rats. A glutamate antagonist plus a gamma-aminobutyric acid agonist. Stroke 25, 189-196.
37. MENNITI, F., CHERNARD, B., COLLINS, M., et al. (1997). CP-101,606, a potent neuroprotectant selective for forebrain neurons. Eur. J. Pharmacol. 331, 117-126.
38. MENNITI, F.S., PAGNOZZI, M.J., BUTLER P., et al. (2000). CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents. Neuropharmacology 39, 1147-1155.
39. MENNITI, F.S., SHAH, A.K., WILLIAMS, S.A., et al. (1998). CP-101,606: an NR2B-selective NMDA receptor antagonist. CNS Drug Rev. 4, 307-322.
40. MERCHANT, R.E., BULLOCK, M.R., CARMACK, C.A., et al. (1999). A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann. N.Y. Acad. Sci. 890, 42-50.
41. MOTT, D.D., DOHERTY, J.J., ZHANG, S., et al. (1998). Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat. Neurosci. 1, 659-667.
42. NASH, J.E., HILL, M.P., and BRORCHIE, J.M. (1999). Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp. Neurol. 155, 42-48.
43. NIKAM, S.S., and MELTZER, L.T. (2002). NR2B selective NMDA receptor antagonists. Curr. Pharm. 8, 845-855.
44. OBRENOVITCH, T.P., URENJAK, J., ZILKHA, E., et al. (2000). Excitotoxicity in neurological disorders-the glutamate paradox. Int. J. Dev. Neurosci. 18, 281-287.
45. OLNEY, J.W., LABRUYERE, J., and PRICE, M.T. (1990). Pathological changes induced in cerebrocortical neurons by phenyclidine and related drugs. Science 244, 1360-1362.
46. OLNEY, J.W., LABRUYERE, J., and WANG, G., et al. (1991). NMDA antagonist neurotoxicity: mechanism and prevention. Science 254, 1515-1518.
47. PARK, C.K., McCULLOCH, J., KANG, J.K., et al. (1992). Efficacy of D-CPPene, a competitive N-methyl-D-aspartate antagonist in focal cerebral ischemia in the rat. Neurosci. Lett. 147, 41-44.
48. PAXINOS, G., and WATSON, C. (1998). The Rat Brain in Stereotaxic Coordinates. Academic Press: San Diego.
49. ROGAWSKI, M.A. (2000). Low-affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents-toward an understanding of their favorable tolerability. Amino Acids 19, 133-149.
50. RUTKAUSKAITĖ, J., WÄGNER, A., BJELKE, B., et al. (1998). NMDA and AMPA antagonists block the functional expression of brain ischemia induced by compression of a specific brain area in rat sensorimotor cortex. Abstracts Society for Neuroscience, Annual Meeting, Los Angeles, CA, Nov. 7-12, 1998.
51. SCHMUED, L.C., ALBERTSON, C., and SLIKKER, W.J. (1997a). Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 751, 37-46.
52. SCHMUED, L.C., and BOWYER, J.F. (1997b). Methamphetamine exposure can produce neuronal degeneration in mouse hippocampal remnants. Brain Res. 759, 135-140.
53. SCHMUED, L., SLIKKER, W., CLAUSING, P., et al. (1999). D-Fenfluramine produces neuronal degeneration in localized regions of the cortex, thalamus, and cerebellum of the rat. Toxicol Sci. 48, 100-106.
54. SHALABY, I.A., CHENARD, B.L., PROCHNIAK, M.A., et al. (1992). Neuroprotective effects of the N-methyl-D-aspartate receptor antagonists ifenprodil and SL-82,0715 on hippocampal cells in culture. J. Pharmacol. Exp. Ther. 26, 925-932.
55. SHEARDOWN, M.J., NIELSEN, E.O., HANSEN, A.J., et al. (1990). 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 247, 517-574.
56. SIMON, R.P., SWAN, J.H., GRIFFITHS, T., et al. (1984). Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 226, 850-852.
57. STEECE-COLLIER, K., CHAMBERS, L.K., JAW-TSAI, S.S., et al. (2000). Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors. Exp. Neurol. 163, 239-243.
58. TANIGUCHI, K., SHINJO, K., MIZUTANI, M., et al. (1997). Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. Br. J. Pharmacol. 122, 809-812.
59. TOULMOND, S., SERRANO, A., BENAVIDES, J., et al. (1993). Prevention by eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18-h) therapeutic window. Brain Res. 620, 32-41.
60. TSUCHIDA, E., RICE, M., and BULLOCK, R. (1997). The neuroprotective effect of the forebrain-selective NMDA antagonist CP101,606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat. J. Neurotrauma 4, 409-417.
61. WARNER, D.S., MARTIN, H., LUDWIG, P., et al. (1995). In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. J. Cereb. Blood Flow Metab. 15, 188-196.
62. WILLIAMS, K., RUSSELL, S.L., SHEN, Y.M., et al. (1993). Developmental switch in the expression of NMDA receptors occurs in vivo and in vitro. Neuron 10, 267-278.
63. YATSUGI, S., TAKAHASHI, M., KAWASAKI-YATSUGI, S., et al. (1996). Neuroprotective effect of YM90K, a novel AMPA/kainate receptor antagonist, in focal cerebral ischemia in cats. J. Cereb. Blood Flow Metab. 16, 959-966.
64. ZWIENENBERG, M., GONG, Q.Z., BERMAN, R.F., et al. (2001). The effect of groups II and III metabotropic glutamate receptor activation on neuronal injury in a rodent model of traumatic brain injury. Neurosurgery 48, 1119-1127.